AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis

Cancer Letters

Volumn 362, Issue 2, 2015, Pages 174-182

  Ren, Yu ^a,b   Zhou, Xuan ^c   Yang, Juan Juan ^a   Liu, Xia ^a   Zhao, Xiao hui ^a   Wang, Qi xue ^a,b   Han, Lei ^a,b   Song, Xin ^a   Zhu, Zhi yan ^a   Tian, Wei ping ^a   Zhang, Lun ^c   Mei, Mei ^a   Kang, Chun sheng ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tian Jin Normal University   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

AC1MMYR2; CDK5; CDK5RAP1; Metastasis; Taxol

Indexed keywords

AC1MMYR2; ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLIN DEPENDENT KINASE 5; FOCAL ADHESION KINASE; MICRORNA 21; PACLITAXEL; PROTEIN P39; RAP1 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; AC1MMYR2 COMPOUND; CDK5 PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR INVASION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST NEOPLASMS; CARCINOGENESIS; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; RANDOMIZATION;

MUS;

ANIMALS; BREAST NEOPLASMS; CARCINOGENESIS; CELL MOVEMENT; CYCLIN-DEPENDENT KINASE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PACLITAXEL; PYRIMIDINES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928203641     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.038     Document Type: Article

References (39)

1. Gupta G.P., Massagué J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
2. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
3. Palena C., Roselli M., Litzinger M.T., Ferroni P., Costarelli L., Spila A., et al. Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. J. Natl Cancer Inst 2014, 106.
4. Weaver B.A. How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell 2014, 25:2677-2681.
5. Yang J.M., Yang G.Y., Medina D.J., Vassil A.D., Liao J., Hait W.N. Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. Biochem. Biophys. Res. Commun 1999, 266:167-173.
6. Quintavalle M., Elia L., Price J.H., Heynen-Genel S., Courtneidge S.A. A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion. Sci. Signal 2011, 4:ra49.
7. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
8. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. J. Pathol 2011, 223:102-115.
9. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer. Rationale, strategies, and challenges. Nat. Rev. Drug Discov 2010, 9:775-789.
10. Lee Y.S., Dutta A. MicroRNAs in cancer. Annu. Rev. Pathol 2009, 4:199-227.
11. Su Y., Li X., Ji W., Sun B., Xu C., Li Z., et al. Small molecule with big role: microRNAs in cancer metastatic microenvironments. Cancer Lett 2014, 344:147-156.
12. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis, and patient poorprognosis. RNA 2008, 14:2348-2360.
13. Volinia S., Galasso M., Sana M.E., Wise T.F., Palatini J., Huebner K., et al. Breast cancer signatures for invasiveness and prognosisdefined by deep sequencing of microRNA. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3024-3029.
14. Hatley M.E., Patrick D.M., Garcia M.R., Richardson J.A., Bassel-Duby R., van Rooij E., et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010, 18:282-293.
15. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
16. Huang Y.H., Lin Y.H., Chi H.C., Liao C.H., Liao C.J., Wu S.M., et al. Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma. Cancer Res 2013, 73:2505-2517.
17. Niu J., Shi Y., Tan G., Yang C.H., Fan M., Pfeffer L.M., et al. DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J. Biol. Chem 2012, 287:21783-21795.
18. Shi Z., Zhang J., Qian X., Han L., Zhang K., Chen L., et al. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res 2013, 73:5519-5531.
19. Eggers J.P., Grandgenett P.M., Collisson E.C., Lewallen M.E., Tremayne J., Singh P.K., et al. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clin. Cancer Res 2011, 17:6140-6150.
20. Pozo K., Castro-Rivera E., Tan C., Plattner F., Schwach G., Siegl V., et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell 2013, 24:499-511.
21. Zheng Q., Han L., Dong Y., Tian J., Huang W., Liu Z., et al. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. Neuro-Oncol 2014, 16:1229-1243.
22. Shi Z., Qian X., Li L., Zhang J., Zhu S., Zhu J., et al. Nuclear translocation of ß-catenin is essential for glioma cell survival. J. Neuroimmune Pharmacol 2012, 7:892-903.
23. Feldmann G., Mishra A., Hong S.M., Bisht S., Strock C.J., Ball D.W., et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 2010, 70:4460-4469.
24. Liang Q., Li L., Zhang J., Lei Y., Wang L., Liu D.X., et al. CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression. Sci. Rep 2013, 3:2932.
25. Huang C., Rajfur Z., Yousefi N., Chen Z., Jacobson K., Ginsberg M.H. Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration. Nat. Cell Biol 2009, 11:624-630.
26. Linder S., Hufner K., Wintergerst U., Aepfelbacher M. Microtubule-dependent formation of podosomal adhesion structures in primary human macrophages. J. Cell Sci 2000, 113:4165-4176.
27. Schoumacher M., Goldman R.D., Louvard D., Vignjevic D.M. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J. Cell Biol 2010, 189:541-556.
28. Reiter V., Matschkal D.M., Wagner M., Globisch D., Kneuttinger A.C., Müller M., et al. The CDK5 repressor CDK5RAP1 is a methylthiotransferase acting on nuclear and mitochondrial RNA. Nucleic Acids Res 2012, 40:6235-6240.
29. Ching Y.P., Pang A.S., Lam W.H., Qi R.Z., Wang J.H. Identification of a neuronal Cdk5 activator-binding protein as Cdk5 inhibitor. J. Biol. Chem 2002, 277:15237-15240.
30. Lu Y., Li T., Qureshi H.Y., Han D., Paudel H.K. Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain. J. Biol. Chem 2011, 286:20569-20581.
31. Saito T., Yano M., Kawai Y., Asada A., Wada M., Doi H., et al. Structural basis for the different stability and activity between the Cdk5 complexes with p35 and p39 activators. J. Biol. Chem 2013, 288:32433-32439.
32. Zavadil J., Narasimhan M., Blumenberg M., Schneider R.J. Transforming growth factor-beta and microRNA: mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs 2007, 185:157-161.
33. Braun J., Hoang-Vu C., Dralle H., Huttelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene 2010, 29:4237-4244.
34. Zheng Y., Xia Y., Hawke D., Halle M., Tremblay M.L., Gao X., et al. FAK phosphorylation by ERK primes Ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol. Cell 2009, 35:11-25.
35. Sulzmaier F.J., Jean C., Schlaepfer D.D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer 2014, 14:598-610.
36. Rea K., Sensi M., Anichini A., Canevari S., Tomassetti A. EGFR/MEK/ERK/CDK5- dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells. Cell Death Dis 2013, 4:e815.
37. Muñoz J.P., Huichalaf C.H., Orellana D., Maccioni R.B. cdk5 modulates beta- and delta-catenin/Pin1 interactions in neuronal cells. J. Cell. Biochem 2007, 100:738-749.
38. Canel M., Serrels A., Frame M.C., Brunton V.G. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J. Cell Sci 2013, 126:393-401.
39. Konze S.A., van Diepen L., Schröder A., Olmer R., Möller H., Pich A., et al. Cleavage of E-cadherin and β-catenin by calpain affects Wnt signaling and spheroid formation in suspension cultures of human pluripotent stem cells. Mol. Cell. Proteomics 2014, 13:990-1007.